Recent FDA action (through November 2008) related to aztreonam lysine, fentanyl buccal, tocilizumab, everolimus, ENB-0040, and artemether/lumefantrine
Formulary Watch
Latest News
All News
Advertisement
Generic drugs approved by FDA (through November 2008) including galantamine extended-release capsules and carbidopa/levodopa orally disintegrating tablets
Recent FDA approvals (through November 2008) related to Gardasil, Gamunex, Alimta, Nasacort AQ, ProAir HFA, Keppra XR, and Taxus Express2 Atom Paclitaxel-Eluting Coronary Stent System
Agents in late-stage development for the treatment of insomnia and restless legs syndrome (RLS)
Year-end "Focus on": News and updates on the novel pharmacologic agents reviewed over the past 12 months; Focus on prasugrel; Pharmaceutical pipeline database products
Merck has announced that they are discontinuing development of taranabant, an investigational selective blocker of the cannabinoid-1 (CB-1) receptor that was being studied for the treatment of obesity.
The Long-Term Intervention on Fractures with Tibolone (LIFT) study demonstrated a reduced risk of vertebral fracture, breast cancer, and possibly colon cancer but a significantly increased risk of stroke in older postmenopausal women treated with tibolone versus those treated with placebo.
FDA announced that the agency has posted on its website a report listing drugs that are being investigated for potential safety concerns.
Genentech informed healthcare professionals that a 70-year-old patient who has been treated with efalizumab (Raptiva) for chronic psoriasis for >4 years has developed progressive multifocal leukoencephalopathy (PML), a rare, progressive disease of the central nervous system that is usually fatal.
Advertisement
In the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, tiotropium therapy for patients with chronic obstructive pulmonary disease (COPD) was associated with long-term improvements in lung function, quality of life, and COPD exacerbations. The therapy did not, however, significantly reduce the rate of decline in forced expiratory volume in 1 second (FEV1) compared with placebo.
Rational approaches to the treatment of mixed dyslipidemia; Focus on eltrombopag; Drug Watch: Agents in late-stage development for the treatment of hepatitis B and C virus infections
Completion of this licensing agreement transferring copyright ownership to Formulary, is required and has to be signed by all article coauthors (a separate form for each author/coauthor of a single manuscript, each showing an original signature is required). The copyright form must not include any written notations other than the original written and printed signature of the author and date. This form should be mailed [not emailed or faxed] to Formulary when the article is submitted for publication consideration.
Drug Watch: Agents in late-stage development for the treatment of hepatitis B and C virus infections (October 2008)
Even though the Medicare prescription drug benefit has provided access to medications at less-than-anticipated cost to the government-and lower out-of-pocket spending for seniors-many Democrats and consumer advocates want to overhaul the program. Critics contend that the federal government can negotiate prices with pharmaceutical companies that are lower than those obtained by private insurers operating prescription drug plans (PDPs), and some reformers charge that the program is too complex and confusing for elderly beneficiaries, pointing particularly to the infamous "donut hole" that is affecting more Medicare patients than anticipated.
A systematic search of the literature published in the International Journal of Clinical Practice demonstrated that angiotensin receptor blockers (ARBs) used as monotherapy or in combination with angiotensin-converting enzyme (ACE) inhibitors are not associated with a beneficial effect on mortality in patients with heart failure (HF).
Labeling updates and warnings through October 2008 for adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), infliximab (Remicade), and rituximab (Rituxan).
A nested case-control analysis published in the Annals of Internal Medicine demonstrated an increased risk of all-cause and cardiovascular mortality among patients with recently diagnosed chronic obstructive pulmonary disease (COPD) treated with ipratropium.
Recent FDA action (through October 2008) related to vernakalant, doripenem, custirsen, droxidopa, amrubicin, dronedarone, and imatinib.
Eltrombopag: A TPO receptor agonist for the treatment of chronic idiopathic thrombocytopenic purpura
Eltrombopag is a TPO receptor agonist that is currently pending FDA approval for the treatment of ITP. This agent has been granted orphan drug and priority review status. In May 2008, the Oncology Drugs Advisory Committee unanimously agreed that eltrombopag demonstrates a favorable risk:benefit profile for the short-term treatment of chronic ITP.
Recent FDA approvals and indications (through October 2008) related to Cancidas, Aloxi, and Vidaza.
New biologic: Romiplostim (Nplate), a thrombopoietin mimetic peptibody, was approved on August 22, 2008, for the treatment of chronic ITP.
New molecular entity: Tetrabenazine (Xenazine), a monoamine depleter, was approved on August 15, 2008, for the treatment of chorea associated with Huntington's disease.
This article reviews the role of individual therapeutic agents and combination therapies that can be used for the treatment of mixed dyslipidemia.
The Comparative Effectiveness Research Act of 2008 would establish the Health Care Comparative Effectiveness Research Institute as a private, nonprofit, nongovernmental entity that would contract with government agencies and private research organizations to conduct systematic reviews, observational studies, and randomized controlled clinical trials to obtain evidence regarding the clinical effectiveness of therapies and treatments.
Primary androgen deprivation therapy does not prolong survival in most patients with prostate cancer
Primary androgen deprivation therapy (PADT), the second most common treatment for localized prostate cancer following prostatectomy, is no more effective than conservative medical management for prolonging survival in most older patients with prostate cancer.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Zepbound linked to lower healthcare costs in older adults with obesity
2
Biosimilars provide modest cost savings for cancer patients, study finds
3
On Medicaid work requirements, the end of ACA enhanced subsidies and ACAP’s 25th anniversary
4
FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients
5